Replies to post #781093 on NorthWest Biotherapeutics Inc (NWBO)

[dennisdave]

I know of Flipper's posts, but he is far off on this.

The SurVaxM trial has not reached primary completion yet. The estimated completion date of 8/2024 is not possible as the IA did not happen until 1/2025. I would take a swag that the primary is at 180 events (typically 70-80% of patients) and the IA would then have been at 90 events (50% of the primary). So they must wait on that. I would guess next year. And then they still have to analyze and publish.

I agree with you that Flippers' theory on this is very far-fetched and probably nonsensical. At this point, Im just a blind NWBO long trying to grasp for reasons why ooh why. But I do believe they received their third RFI in May or June 2025.

There is no reason yet to assume the trial failed.

ooh come on ex. If you are holding the same standards for SurVaxM as you have for DCVAXL over the years then you would conclude that SurVaxM is DOA.